Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

Returns on capital

Forte Biosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-113.7%

avg -107.7%

ROIC

-113.9%

avg -64.6%

ROA

-83.8%

avg -59.6%

Analysis

ROA is currently the strongest return metric at -83.8% versus its period average of -59.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Paul A. Wagner

Chief Executive Officer, President & ChairmanUSD 1.41M562.50K0.02%

Antony A. Riley

Chief Financial OfficerUSD 632.95K59750<0.01%

Barbara K. Finck

Senior Medical Clinician & DirectorUSD 600K7931.00K0.22%

Christopher Roenfeldt

Chief Operating Officer————

Compensation is shown in the reported currency; data updated Aug 29, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$254,832.78

Sells

0

$0.00

Net Transaction Value

+$254,832.78

Net buying

Most Active

Riley Antony A

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Dec 30, 25

Riley Antony A

Direct

Buy$254.8K

Summary

Insiders reported 1 buys worth $254,832.78 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $254,832.78. Riley Antony A was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Forte Biosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about FBRX's management, answered from reported figures.

Who manages FBRX?

Forte Biosciences, Inc. (FBRX) lists 4 active executives. The top listed executive is Barbara K. Finck, Senior Medical Clinician & Director.

Are FBRX insiders buying or selling?

Recent insider activity shows net buying of $29.71M.